Abstract
Understanding the immune response upon infection with the filarial nematode Onchocerca volvulus and the mechanisms that evolved in this parasite to evade immune mediated elimination is essential to expand the toolbox available for diagnostics, therapeutics and vaccines development. Using high-density peptide microarrays we scanned the proteome-wide linear epitope repertoire in Cameroonian onchocerciasis patients and healthy controls from Southern Africa which led to the identification of 249 immunodominant antigenic peptides. Motif analysis learned that 3 immunodominant motifs, encompassing 3 linear epitopes, are present in 70, 43, and 31 of these peptides, respectively and appear to be scattered over the entire proteome in seemingly non-related proteins. These linear epitopes are shown to have an atypical isotype profile dominated by IgG1, IgG3, IgE and IgM, in contrast to the commonly observed IgG4 response in chronic active helminth infections. The identification of these linear epitope motifs may lead to novel diagnostic development but further evaluation of cross-reactivity against common co-infecting human nematode infections will be needed.
Highlights
On the World Health Organization (WHO) list of Neglected Tropical Diseases (NTD), 17 infectious diseases are listed [1], eight of them caused by a helminth infection [2]
Infection with the filarial parasite Onchocerca volvulus is the cause of river blindness
We analyzed the immune response against this parasite in infected individuals in order to identify linear epitopes
Summary
On the World Health Organization (WHO) list of Neglected Tropical Diseases (NTD), 17 infectious diseases are listed [1], eight of them caused by a helminth infection [2]. Onchocerciasis (or river blindness) is caused by infection with the filarial nematode Onchocerca volvulus. A lateral flow assay for the detection of IgG4 antibodies to the parasitic antigen Ov-16 was developed and significantly improved the ease of detection of Onchocerca infection [6,7,8,9]. Not all individuals with patent infections are developing (IgG4) antibodies to the Ov-16 antigen [10]. The reason for this is not understood, but it illustrates that a one-single antibody test for epidemiological surveillance purposes is not fully adequate to establish true infection prevalence
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.